Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First

Similar CAR-T Will Carry The Same Cost As Yescarta

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.